| Balance Sheets | 2025-10-31 | 2025-07-31 | ||
|---|---|---|---|---|
| Cash | 4,449,433 | 5,620,872 | ||
| Prepaid expenses and other current assets | 272,015 | 307,958 | ||
| Total current assets | 4,721,448 | 5,928,830 | ||
| Property, plant and equipment, net | 370,236 | 397,921 | ||
| Total assets | 5,091,684 | 6,326,751 | ||
| Accounts payable and accrued liabilities | 717,488 | 983,311 | ||
| Total liabilities, all current | 717,488 | 983,311 | ||
| Preferred stock, value-Series BPreferred Stock | - | 0 | ||
| Preferred stock, value-Series CPreferred Stock | - | 0 | ||
| Common stock, 0.0001 par value 300,000,000 shares authorized 3,801,604 and 778,733 issued and outstanding as of october 31, 2025 and april 30, 2025, respectively | 380 | 314 | ||
| Additional paid-in capital | 66,612,519 | 66,581,071 | ||
| Accumulated deficit | -62,238,703 | -61,237,945 | ||
| Total stockholders equity | 4,374,196 | 5,343,440 | ||
| Total liabilities and stockholders equity | 5,091,684 | 6,326,751 | ||
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc. (ALZN)